Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Bayer bonds, Nestle investment, P&G and Abbott earnings, NAD reviews

This article was originally published in The Tan Sheet

Executive Summary

Bayer targets acquisitions with bond proceeds; Nestle commits $1 bil. to Mexico expansion; P&G health care sales grow 4%; U.S. sales slow Abbott Nutrition; NAD refers Grey Defence to FTC; Rainbow Light pulls anti-aging claims; and medical food warning letter.

You may also be interested in...



Major OTC Acquisitions, Expansion Likely In 2014

With major consumer product divisions potentially in play, analysts take a look at possible buyers and sellers in the OTC space. Switches and consumer business expansion plans are also likely to shape 2014.

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.

Day One Springs Into Commercial Action With Ojemda Approval

The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel